74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Rhythm Pharmaceuticals Inc
Open
SectorHealthcare
50.18 -1.61
Overview
Share price change
24h
Min
49.24
Max
52.24
Income | 385K -43M |
|---|---|
Sales | 8.6M 42M |
EPS | -0.72 |
Profit margin | -103.495 |
Employees | 283 |
EBITDA | 806K -38M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +44.69% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | 104M 3.5B |
|---|---|
Previous open | 51.79 |
Previous close | 50.18 |
News Sentiment
By Acuity
50%
50%
180 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Rhythm Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Rhythm Pharmaceuticals Inc Forecast
Price Target
By TipRanks
44.69% upside
12 Months Forecast
Average 75.18 USD 44.69%
High 94 USD
Low 60 USD
Based on 11 Wall Street analysts offering 12 month price targets forRhythm Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
180 / 386 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
